Scilex Holding Co (Scilex Holding Co) Interest Expense : $-1.60 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scilex Holding Co's interest expense for the three months ended in Mar. 2024 was $ -0.53 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.60 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scilex Holding Co's Operating Income for the three months ended in Mar. 2024 was $ -26.37 Mil. Scilex Holding Co's Interest Expense for the three months ended in Mar. 2024 was $ -0.53 Mil. Scilex Holding Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scilex Holding Co Interest Expense Historical Data

The historical data trend for Scilex Holding Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co Interest Expense Chart

Scilex Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-16.89

-13.12

-39.76

-9.60

-1.07

Scilex Holding Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial							-	-0.01	-0.51	-0.55	-0.53

Scilex Holding Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60 Mil.

Scilex Holding Co (NAS:SCLX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scilex Holding Co's Interest Expense for the three months ended in Mar. 2024 was $-0.53 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-26.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $18.39 Mil.

Scilex Holding Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Scilex Holding Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Scilex Holding Co (Scilex Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.

Executives

Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji	director	25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632